Analysis of the use of novel antitumor drugs in lung cancer treatment at Nanjing Chest Hospital from 2019 to 2023

Objective To monitor the clinical use and trend of novel antitumor drugs in the treatment of lung cancer，and provide references for improving the standardization and rationality of drug use and the optimization of relevant medical insurance policies. Methods A retrospective method was used to analyze the number of novel antitumor drugs in the treatment of lung cancer，annual sales amount，defined daily doses（DDDs），defined daily dose cost（DDC），and ratio of sequence of consumption sum（B）/sequence of DDDs（A）in the Nanjing Brain Hospital（Thoracic Hospital Campus）from 2019 to 2023. Results From 2019 to 2023，the variety，consumption sum and constituent ratio of novel antitumor drugs in the treatment of lung cancer showed an increasing trend year by year，and the increase in consumption sum was stable. From 2019 to 2023，the varieties of novel antitumor drugs increased significantly，with the largest increase in the use of camrelizumab injection,the DDC of various novel antitumor drugs showed a downward trend，among which the DDC of afatinib dimaleate tablets in small molecule targeted drugs had the largest decline,the largest decrease in DDC for monoclonal antibody drugs was camrelizumab injection，from 942.76 Yuan to 123.85 Yuan，with a B/A ratio greater than 1，indicating good synchronization. Conclusion The variety and quantity of novel antitumor drugs in this hospital have increased significantly，and the treatment payment of patients has decreased year by year.